Availability of universal marker for the diagnosis of platelet apoptosis is an important but currently unresolved goal of platelet physiology investigations. Mitochondrial inner transmembrane potential (DCm) depolarization is frequently used as a marker of apoptosis in nucleated cells and anucleate platelets. Since DCm depolarization in platelets is also frequently associated with concurrent induction of other apoptotic responses, it may appear that DCm depolarization is a good universal marker of platelet apoptosis. However, data presented in the current study indicate that this is incorrect. We report here fundamental differences in the effects of potassium ionophore valinomycin and calcium ionophore A23187 on human platelet apoptosis. Although both A23187-triggered and valinomycin-triggered DCm depolarization are strongly induced, the former is dependent on the opening of mitochondrial permeability transition pore (MPTP) and the latter is MPTP-independent. Furthermore, effects of calcium and potassium ionophores on other apoptotic events are also basically different. A23187 induces caspase-3 activation, proapoptotic Bax and Bak protein expression, phosphatidylserine exposure, and microparticle formation, whereas valinomycin does not induce these apoptotic manifestations. Discovery of targeted DCm depolarization not associated with apoptosis in valinomycin-treated platelets indicates that this marker should not be used as a single universal marker of platelet apoptosis in unknown experimental and clinical settings as it may lead to a false-positive apoptosis diagnosis.
Introduction
The definition of a valid universal marker that may be used for the diagnosis of platelet apoptosis is an important but currently unresolved goal of platelet physiology investigations. A perfect marker should be easily methodically determined and able to predict the presence or absence of platelet apoptosis in unknown tested experimental and clinical conditions. The role of the mitochondrial pathway in control of apoptosis is well documented for nucleated cells. [1] [2] [3] Dissipation of the mitochondrial inner transmembrane potential (DCm depolarization) determined by cell-penetrating potentiometric dyes is frequently used for detecting apoptosis in nucleated cells 1, 2, 4 and anucleate platelets. 5 In the review on platelet apoptosis 5 and other papers, 6-8 many experimental situations are described where DCm depolarization in platelets has been induced by different triggers, including platelet agonists, calcium (Ca 2þ ) ionophores, proapoptotic BH3 mimetic ABT-737, high shear stresses, and platelet storage.
Induction of DCm depolarization in platelets is associated with concurrent induction of other apoptotic responses, such as opening of mitochondrial permeability transition pore (MPTP), cytochrome c release from mitochondria to the cytosol, activation of caspases-3, -8, and -9, expression of proapoptotic members of Bcl-2 family proteins (Bax, Bak, and Bid), cleavage of apoptosis-associated cytoskeleton proteins (gelsolin, actin, and moesin), phosphatidylserine (PS) exposure on the platelet surface, platelet shrinkage, and platelet-derived microparticle (MP) formation ( Table 3 in the review 5 and reseach papers [6] [7] [8] [9] [10] [11] . Although from these studies [5] [6] [7] [8] [9] [10] [11] it may appear that DCm depolarization is a good universal marker of platelet apoptosis, data presented in the current report indicate that this is incorrect.
Investigating the effects of potassium (K þ ) ionophore valinomycin and Ca 2þ ionophore A23187 on platelet apoptosis, we demonstrate that, in contrast to Ca 2þ ionophore, which induces DCm depolarization together with other biochemical and cellular manifestations of platelet apoptosis, in platelets treated with K þ ionophore valinomycin, strong DCm depolarization is not accompanied by the induction of other markers of platelet apoptosis. These data indicate that even strong DCm depolarization, when detected in unknown tested conditions, cannot be considered an unequivocal marker of platelet apoptosis, and simultaneous determination of other apoptotic markers is required for validation of apoptosis in platelets.
Materials and Methods

Reagents and Solutions
Bovine serum albumin (BSA), dimethyl sulfoxide (DMSO), 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), phosphate-buffered saline (PBS), cyclosporin A (CsA), and fluorescein isothiocyanate (FITC)-conjugated F(ab 0 ) 2 fragment of goat antirabbit immunoglobulin G (IgG) were purchased from Sigma (St Louis, Missouri). Valinomycin and A23187 were purchased from Calbiochem (San Diego, California). Fluorescent dye JC-1 (5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide) was purchased from Invitrogen (Carlsbad, California), and FAM-DEVD-FMK (carboxyfluorescein-carbonyl-aspartyl-glutamylvalyl-aspartic acid fluoromethyl ketone) was purchased from Chemicon International (Temecula, California). The FITC-conjugated annexin V was purchased from BD Biosciences (San Jose, California). Rabbit anti-Bax (P-19), anti-Bak (G-23), and anti-Bcl-2 (N-19) IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, California). The FITCconjugated antiglycoprotein IIb/IIIa (anti-GPIIb/IIIa) antibody (anti-CD41-FITC, clone P2) was purchased from Beckman-Coulter (Westbrook, Maine).
Stock solutions of valinomycin (1.0 mmol/L), A23187 (10 mmol/L), and CsA (10 mmol/L) were dissolved in DMSO. Buffer A was composed of PBS supplemented with 1 mmol/L MgCl 2 , 5.6 mmol/L glucose, 0.1% BSA, and 10 mmol/L HEPES, pH 7.4. Buffer B was composed of buffer A containing 0.11% DMSO; it was used for dilution of platelet-rich plasma (PRP), preparation of working solutions of valinomycin (5 or 6 mmol/L), A23187 (50 or 60 mmol/L), and CsA (50 mmol/L) for the treatment of platelets, and as the control diluent buffer for the determination of platelet apoptotic events by flow cytometry.
Preparation and Treatment of Platelets with Valinomycin and A23187
Human blood collection and all experimental protocols were approved by the research ethics board of St Michael's Hospital (Toronto, Ontario, Canada), the methods were carried out in accordance with the approved guidelines, and informed consent was obtained from all participants.
Venous blood from healthy volunteers was anticoagulated with 0.32% sodium citrate. The Platelet-rich plasma (PRP) was obtained by centrifugation at 180g for 15 minutes at room temperature (RT) followed by dilution 1:10 with buffer B (for assays of DCm, caspase-3, Bax, Bak, and Bcl-2 proteins, and MPs) or 1:60 (for PS assay).
Platelet apoptotic events were determined in 3 platelet groups treated with (1) diluent buffer B, (2) 1 mmol/L valinomycin, 12 and (3) 10 mmol/L A23187. 6, 9, 11 For this, 40 mL of diluted PRP aliquots was incubated for 15 minutes at RT with 10 mL of buffer B, 5 mmol/L valinomycin in buffer B, and 50 mmol/L A23187 in buffer B, respectively.
Treatment of Platelets with CsA in Combination with Valinomycin, A23187 or Control Diluent
The CsA was used to analyze the effects of MPTP on DCm depolarization in platelets treated with valinomycin, A23187, or control diluent (buffer B). Six platelet groups were treated at RT with (1) diluent, (2) 10 mmol/L CsA plus diluent, (3) 1 mmol/L valinomycin, (4) 10 mmol/L CsA plus 1 mmol/L valinomycin, (5) 10 mmol/L A23187, and (6) 10 mmol/L CsA plus 10 mmol/L A23187. All platelet treatments were performed with 40 mL of PRP aliquots by dilution of 1:10 with buffer B in a total volume of treatment mixture of 60 mL. For diluenttreated platelet group (1), 40 mL PRP was incubated for 45 minutes with 20 mL buffer B. For CsA plus diluent-treated platelet group (2), 40 mL PRP was preincubated for 30 minutes with 10 mL of 50 mmol/L CsA in buffer B, followed by incubation for 15 minutes with 10 mL buffer B. For valinomycintreated or A23187-treated platelet groups (3) and (5), 40 mL PRP was preincubated for 30 minutes with 10 mL buffer B, followed by incubation for 15 minutes with 10 mL of 6 mmol/L valinomycin or 60 mmol/L A23187 in buffer B. For CsA plus valinomycin-treated or CsA plus A23187-treated platelet groups (4) and (6), 40 mL PRP was preincubated for 30 minutes with 10 mL of 50 mmol/L CsA in buffer B, followed by incubation for 15 minutes with 10 mL of 6 mmol/L valinomycin or 60 mmol/L A23187 in buffer B.
Determination and Analysis of Platelet Apoptotic Markers
After preparation of appropriately treated platelet samples, platelet apoptosis was determined by flow cytometry (FACSCalibur; BD Biosciences). For this, platelets were incubated with fluorescent probes specific for each of the 7 apoptotic markers, including DCm depolarization, caspase-3 activation, Bax, Bak, and Bcl-2 protein expression, PS exposure, and MP formation. From each platelet sample, diluted to a final volume of 500 mL with buffer B, 20 000 events were acquired and platelets were detected in the platelet-specific forward scatter (FSC)-side scatter (SSC) gate followed by fluorescence dot plot or histogram analysis using CellQuest Pro, FlowJo 7.4, and FCS Express 3.0 Software (BD Biosciences).
Determination of DCm depolarization in platelets was performed by fluorescent cell-penetrating cationic dye JC-1. 1, 9, 13, 14 The JC-1 working solution was prepared as described previously. 9 Aliquots of platelet samples were incubated with JC-1 solution, acquired for flow cytometry, and platelet-bound JC-1 monomers, detected by green fluorescence 1 (FL1), and JC-1 aggregates, detected by red fluorescence 2 (FL2), were analyzed as FL1-FL2 dot plots. Depolarization of DCm was determined as the percentage depolarized cells, which is expressed as the increase in the percentage platelets with low FL2. 9 Determination of caspase-3 activation in platelets was performed by flow cytometry using cell-penetrating fluorescein-labeled tetrapeptide FAM-DEVD-FMK as previously described. 9 The FL1 histograms were analyzed and caspase-3 activation was quantified as the mean channel fluorescence (MCF) of platelet-bound FAM-DEVD-FMK probe. Determination of Bax, Bak, and Bcl-2 proteins. Expression of Bcl-2 family proteins was determined by flow cytometry in fixed, permeabilized platelets, using rabbit antihuman anti-Bax, anti-Bak, and anti-Bcl-2 IgG followed by incubation with FITC-conjugated F(ab 0 ) 2 fragment of goat antirabbit IgG as previously described. 15 Platelet samples were acquired and gated, and FL1 histograms were analyzed. Bax, Bak, and Bcl-2 proteins were quantified as the MCF of platelet-bound fluorescent F(ab 0 ) 2 IgG fragment. Determination of PS exposure on the platelet surface was performed by flow cytometry using FITC-conjugated annexin V. After treatment of platelets with valinomycin, A23187, or diluent buffer B, 45 mL aliquots of platelet samples was mixed with 5 mL of buffer B containing 20 mmol/L CaCl 2 to obtain the final CaCl 2 concentration of 2 mmol/L and incubated in the dark for 15 minutes at RT with 3 mL annexin V-FITC. Buffer B (450 mL) containing 2 mmol/L of CaCl 2 was then added, and samples were acquired, gated, and analyzed by FSC-FL1 dot plots. The PS exposure was determined as the percentage annexin V-positive cells. 9 Determination of platelet-derived MP formation. Enumeration of MPs was performed as described previously in the MP-specific gate using staining of platelet samples with the FITC-conjugated anti-GPIIb/IIIa antibody. 7
Statistical Analysis
Data were analyzed using GraphPad Prism 5 software (Graph-Pad Software, San Diego, California) and presented as means with standard error of the mean. The statistical significance of the differences between platelet groups was determined by 1way analysis of variance with Dunnett multiple comparison test and Student t test as appropriate. Differences were considered significant when P < .05.
Results
Mitochondria of nucleated cells respond promptly to the Ca 2þ overload, stimulated by Ca 2þ ionophore A23187, with a rapid accumulation of the cation in the mitochondrial matrix. 4, [16] [17] [18] Calcium influx to mitochondria causes DCm depolarization, opening of the MPTP in the mitochondrial inner membrane (MIM), followed by mitochondrial matrix swelling, rupture of the MIM and the mitochondrial outer membrane (MOM), and release of proapoptotic proteins from mitochondria to the cytosol. 2, 4, [17] [18] [19] [20] Treatment of nucleated cells with the K þ ionophore valinomycin facilitates the movement of K þ ions through the MIM down to electrochemical potential gradient, causing DCm depolarization. 14, 21 Valinomycin is highly selective for K þ over sodium (Na þ ) and Ca 2þ ions 22, 23 and acts preferentially on the mitochondrial rather than on the plasma membrane. 24 In contrast to mitochondrial Ca 2þ influx, stimulated by A23187, mitochondrial K þ influx, stimulated by valinomycin, [24] [25] [26] [27] does not result in MPTP opening in the MIM 19, 28 and massive mitochondrial matrix swelling. 19, 29 Due to these basic differences in the effects of Ca 2þ ionophore A23187 and K þ ionophore valinomycin on mitochondria in nucleated cells, in the current study, we investigated the effects of A23187 and valinomycin on DCm depolarization and other manifestations of apoptosis in anucleate platelets.
Effects of Valinomycin and A23187 on Platelet DCm Depolarization
As shown in Figure 1 , both A23187 and valinomycin strongly induce DCm depolarization in platelets, when 57.8% + 8.4% and 94.0% + 1.1% of cells, respectively, have the MIM with dissipated membrane potential, in comparison with 12.5% + 4.0% of cells in the control diluenttreated platelets (P < .001).
Dependence of Valinomycin-Induced and A23187-Induced DCm Depolarization on the MPTP Opening in Platelets
Using CsA, a potent and specific MPTP inhibitor, 1, 2, 8, 9, 30, 31 we investigated the role of the MPTP opening in platelet DCm depolarization triggered by Ca 2þ and K þ ionophores. As shown in Figure 2 , A23187-induced DCm depolarization is completely inhibited by pretreatment of platelets with CsA, indicating that depolarization induced by Ca 2þ ionophore is dependent on MPTP opening. In contrast, we found that DCm depolarization induced by the K þ ionophore valinomycin is not inhibited by CsA and independent on MPTP opening ( Figure 2 ).
Effects of Valinomycin and A23187 on Extra-Mitochondrial Manifestations of Platelet Apoptosis
We further demonstrated that the effects of A23187 and valinomycin on extra-mitochondrial biochemical and cellular manifestations of platelet apoptosis are also fundamentally different (Figures 3-6 ). Treatment of platelets with Ca 2þ ionophore induces activation of apoptosis executioner caspase-3 ( Figure 3 ), expression of proapoptotic Bax and Bak proteins, but not antiapoptotic Bcl-2 protein ( Figure  4 ), and PS exposure on the platelet surface ( Figure 5 ). On the contrary, K þ ionophore does not induce these biochemical apoptotic events (Figures 3-5 ). Furthermore, A23187 strongly induces MP formation, a cellular manifestation of platelet apoptosis, whereas valinomycin does not stimulate MP formation ( Figure 6 ).
Discussion
Effects of Valinomycin and A23187 on DCm Depolarization, MPTP Opening, and Other Manifestations of Apoptosis in Platelets and Nucleated Cells Table 1 summarizes the results of the current study on the effects of Ca 2þ ionophore A23187 and K þ ionophore valinomycin on mitochondrial (Figures 1 and 2) and extramitochondrial biochemical (Figures 3-5 ) and cellular ( Figure  6 ) manifestations of platelet apoptosis. As shown in the Table  1 , both Ca 2þ and K þ ionophores strongly induce DCm depolarization in human platelets. However, the mechanisms involved in the stimulation of DCm depolarization by these ionophores are different. The Ca 2þ ionophore induces DCm depolarization by MPTP-dependent process through MPTP opening in the MIM. In contrast, DCm depolarization induced by K þ ionophore is independent of MPTP opening (Figure 2) . Furthermore, A23187 induces extra-mitochondrial biochemical and cellular manifestations of platelet apoptosis, including caspase-3 activation, expression of proapoptotic Bax and Bak proteins, PS exposure, and MP formation, whereas valinomycin does not induce these apoptotic events. Hence, we demonstrate for the first time that the K þ ionophore valinomycin accomplishes only targeted triggering of DCm depolarization but does not induce platelet apoptosis. Figure 7 presents the results obtained in this study together with the data reported by others on the effects of these ionophores on the processes associated with the intrinsic (mitochondrial) pathway of apoptosis in nucleated cells, including (1) mitochondrial Ca 2þ and K þ influxes, (2) MPTP opening in the MIM, (3) mitochondrial matrix swelling, (4) MIM and MOM rupture, and (5) release of proapoptotic proteins from mitochondrial matrix and/or mitochondrial intermembrane space (IMS) to the cytosol (references a-j in Figure 7 legend). Figure 7A shows that the mitochondrial Ca 2þ overloading influx induced by A23187 4,16-18 triggers strong MPTPdependent DCm depolarization in platelets, which is inhibited by CsA and mediated by MPTP opening in the MIM. By contrast, as seen in Figure 7B , the strong DCm depolarization triggered by valinomycin-induced K þ influx [24] [25] [26] [27] is MPTPindependent, not inhibited by CsA, and occurs in the absence . Expression of proapoptotic Bax and Bak proteins and antiapoptotic Bcl-2 protein in platelets treated with potassium ionophore valinomycin and calcium ionophore A23187. Platelets were treated with diluent buffer B, 1 mmol/L valinomycin, and 10 mmol/L A23187, fixed and permeabilized. The Bcl-2 family proteins were determined using anti-Bax, anti-Bak, and anti-Bcl-2 IgG followed by anti-IgG fluorescent probe. Expression of Bax, Bak, and Bcl-2 proteins was analyzed by FL1 histograms (A, C, E) and quantified by determining the MCF (B, D, F). Means and SEM for 6 to 7 experiments and differences between A23187-treated and valinomycin-treated platelet groups versus diluent-treated platelet group are presented (B, D, F). Note that A23187 significantly induces expression of proapoptotic Bax (***P < .001) and Bak (**P < .01) proteins, whereas valinomycin does not induce expression of these proteins (ns: P > .05; B and D). Both A23187 and valinomycin do not affect the expression of antiapoptotic Bcl-2 protein (E and F). This result indicates that strong DCm depolarization (Figure 1) does not promote the expression of proapoptotic Bax and Bak proteins in valinomycin-treated platelets. FL1, indicates fluorescence 1; IgG, immunoglobulin G; MCF, mean channel fluorescence; ns, nonsignificant; SEM, standard error of the mean; DCm, transmembrane potential of the mitochondrial inner membrane. of MPTP opening. As shown in Figure 7A , data obtained on isolated mitochondria of nucleated cells treated with Ca 2þ demonstrated MPTP opening in the MIM, 2, 4, 17, 18, 20 massive mitochondrial matrix swelling, MIM and MOM rupture, 2, 4, 17, 19, 20 and release of proapoptotic proteins both from IMS and mitochondrial matrix. 4, 17, 19 In contrast, valinomycintreated nucleated cell mitochondria ( Figure 7B ) are characterized by the absence of MPTP opening, 19, 28 no massive matrix swelling and the absence of MIM and MOM rupture, 19, 29 and no or limited release of proapoptotic proteins from IMS but not from the mitochondrial matrix. 19 However, it has been reported that effects of valinomycin and other K þ ionophores on apoptosis in nucleated cells are dependent on cell type. Valinomycin-treated Chinese hamster ovary cells exhibit several apoptotic events, including DCm depolarization, caspase-3 activation, and PS exposure. 32 In murine hematopoietic cells, valinomycin triggers DCm depolarization, and inhibition of MPTP prevents subsequent valinomycin-induced DCm depolarization. 33 In rat ascites hepatoma (AH-130) cells, valinomycin induces caspase-3 activation and cell shrinkage, as well as uncoupling of respiration and DCm depolarization, suggesting that this type of tumor cells may reflect a mechanism transmitting the signal from DCm depolarization to subsequent execution steps of apoptosis. 34 In primary mouse microglia and astrocytes and cell lines (BV-2, C6, and HEK 293), on the other hand, valinomycin promotes an alternative autophagic form of cell death rather than apoptosis. 35 In the erythroleukemic K562 cell line, the K þ exchanger nigericin and K þ ionophore valinomycin trigger DCm depolarization, and the pretreatment of cells with CsA fails to protect K562 cells from the loss of DCm induced by intracellular K þ flux manipulations. 28 During the treatment of platelets by valinomycin, this K þ ionophore may have other effects beyond DCm depolarization. It may be speculated that alternative forms of platelet cell death occur in platelets treated with valinomycin. As in nucleated cells, other consequences of DCm depolarization may occur Figure 5 . Exposure of PS on the surface of platelets treated with potassium ionophore valinomycin and calcium ionophore A23187. Platelets were treated with diluent buffer B (A), 1 mmol/L valinomycin (B), and 10 mmol/L A23187 (C), and PS exposure was determined by FITC-conjugated annexin V (FL1). Numbers above horizontal lines in panels (A-C) represent the percentage cells with exposed PS. Means and SEM for 10 experiments and differences between A23187-treated and valinomycin-treated platelet groups versus diluent-treated platelet group are presented (D). Note that A23187 significantly and strongly induces aberrant PS exposure on the platelet surface (***P < .001), whereas valinomycin does not induce PS exposure (ns: P > .05). This result indicates that strong DCm depolarization in valinomycintreated platelets (Figure 1 ) does not promote PS exposure. FITC indicates fluorescein isothiocyanate; FL1, fluorescence 1; PS, phosphatidylserine; SEM, standard error of the mean; DCm, transmembrane potential of the mitochondrial inner membrane. in anucleate platelets, including energy starvation by uncoupling of respiration and DCm depolarization 34 and the autophagic form of cell death rather than apoptosis. 35 To examine these options, oxidative phosphorylation and autophagy may be tested in valinomycin-treated platelets downstream of DCm depolarization. (Figures 1-6 ), as well as data obtained by others in nucleated cells (references a-j ). Note that effects of mitochondrial calcium (Ca 2þ ) influx induced by Ca 2þ ionophore A23187 and potassium (K þ ) influx induced by K þ ionophore valinomycin on DCm depolarization and other manifestations of platelet apoptosis are fundamentally different. (A and B) , Both Ca 2þ and K þ influxes trigger strong DCm depolarization in platelets (Figure 1 ), but A23187-induced DCm depolarization is MPTP-dependent ( Figure  2) , whereas valinomycin-induced DCm depolarization is MPTP-independent ( Figure 2 ). Mitochondrial Ca 2þ influx induces biochemical and cellular manifestations of platelet apoptosis (A: Figures 3-6 
Conclusions and Biomedical Significance
From the above characterization of the relationships between DCm depolarization and other mitochondrial (MPTP opening) and extra-mitochondrial manifestations of apoptosis in platelets treated with Ca 2þ ionophore A23187 and K þ ionophore valinomycin, we make the following conclusions.
Differing Effects of Mitochondrial Ca 2þ and K þ Influxes on Platelet Apoptosis
We show a fundamental difference between the impact of mitochondrial Ca 2þ influx, induced by Ca 2þ ionophore A23187, and mitochondrial K þ influx, induced by K þ ionophore valinomycin, on platelet apoptosis. Since strong DCm depolarization can occur both in the presence (A23187 treatment) and in the absence (valinomycin treatment) of MPTP opening ( Figure  2 ), it appears that DCm depolarization does not require participation of MPTP-dependent mechanism of the mitochondrial membrane permeabilization. Furthermore, it was shown that Ca 2þ influx triggers platelet apoptosis ( Figure 7A ), whereas K þ influx does not cause apoptosis ( Figure 7B ).
Depolarization of DCm is not a Universal Marker of Apoptosis in Anucleate Platelets
Presented data demonstrate that strong DCm depolarization can be achieved by both modes of platelet treatment-with Ca 2þ and K þ ionophores. In the case of treatment with Ca 2þ ionophore A23187, DCm depolarization triggered by mitochondrial Ca 2þ overloading influx is associated with induction of other manifestations of platelet apoptosis and represents apoptotic marker (Figure 7A ). However, with valinomycin-treated platelets, DCm depolarization is not associated with platelet apoptosis and cannot be considered as an apoptotic marker ( Figure 7B ). Hence, DCm depolarization is not a universal marker of platelet apoptosis but, depending on experimental and clinical conditions, may also represent a nonapoptotic marker characterizing electrochemical potential of the MIM not relevant to platelet apoptosis.
Discovery of Nonapoptogenic DCm Depolarization in Platelets
Our experiments performed on valinomycin-treated platelets demonstrate that DCm depolarization per se is not an apoptogenic factor (ie, this mitochondrial event is not causal for platelet apoptosis), since even strong valinomycin-induced DCm depolarization, when almost all cells in platelet population have depolarized MIM (Figure 1 ), does not trigger biochemical and cellular manifestations of apoptosis in anucleate platelets ( Table 1) .
Permeabilization of the MIM as an Apoptogenic Factor in Platelets
Mitochondrial inner membrane permeabilization rather than DCm depolarization may be a primary apoptogenic factor of platelet apoptosis. Previously, we found that pretreatment of A23187-stimulated platelets with MPTP inhibitor CsA completely prevents A23187-induced DCm depolarization, caspase-3 activation, platelet shrinkage, and MP formation and partially inhibits PS exposure. 9 The results of the current study (Figures 1-6 ) and data obtained from mitochondria of nucleated cells (references a-j in Figure 7 ) together suggest that permeabilization of the MIM executed via MPTP opening (if followed by massive mitochondrial matrix swelling, MIM and MOM rupture, and release of proapoptotic proteins from IMS and mitochondrial matrix to the cytosol), rather than DCm depolarization, may be a primary apoptogenic event of intrinsic pathway of platelet apoptosis, which determines execution or nonexecution of apoptosis in A23187-treated and valinomycintreated platelets, respectively (Figure 7 ).
Diagnosis of Platelet Apoptosis by DCm Depolarization
The current work indicates that the detection of platelet DCm depolarization in unknown tested experimental and clinical conditions is insufficient for the diagnosis of platelet apoptosis, and determination of other apoptotic markers is required in order to avoid a false-positive conclusion.
Targeted Triggering of DCm Depolarization by Valinomycin as a Model for Analyzing Platelet Functions and Clearance
Targeted valinomycin-induced DCm depolarization in platelets may be a useful experimental model for studying the role of DCm depolarization in different platelet reactions and functions, including platelet hemostatic function and platelet clearance.
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